J
Janet L. Davis
Researcher at University of Miami
Publications - 264
Citations - 12818
Janet L. Davis is an academic researcher from University of Miami. The author has contributed to research in topics: Visual acuity & Uveitis. The author has an hindex of 55, co-authored 249 publications receiving 11386 citations. Previous affiliations of Janet L. Davis include Bascom Palmer Eye Institute & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies
Steven D. Schwartz,Carl D. Regillo,Byron L. Lam,Dean Eliott,Philip J. Rosenfeld,Ninel Z. Gregori,Jean-Pierre Hubschman,Janet L. Davis,Gad Heilwell,Marc J. Spirn,Joseph I. Maguire,Jane Bateman,Rosaleen Ostrick,Debra Morris,Matthew Vincent,Eddy Anglade,Lucian V. Del Priore,Robert Lanza +17 more
TL;DR: The results suggest that hESC-derived cells could provide a potentially safe new source of cells for the treatment of various unmet medical disorders requiring tissue repair or replacement.
Journal ArticleDOI
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Anne E. Fung,Geeta A. Lalwani,Philip J. Rosenfeld,Sander R. Dubovy,Stephan Michels,William J. Feuer,Carmen A. Puliafito,Janet L. Davis,Harry W. Flynn,Maria Esquiabro +9 more
TL;DR: In this paper, an optical coherence tomography (OCT)-guided, variable-dosing regimen with intravitreal ranibizumab for the treatment of patients with age-related macular degeneration (AMD) was evaluated.
Journal ArticleDOI
A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Geeta A. Lalwani,Philip J. Rosenfeld,Anne E. Fung,Sander R. Dubovy,Stephen Michels,William J. Feuer,Janet L. Davis,Harry W. Flynn,Maria Esquiabro +8 more
TL;DR: The PrONTO Study using an OCT-guided variable-dosing regimen with intravitreal ranibizumab resulted in VA outcomes comparable with the outcomes from the phase III clinical studies, but fewer intravItreal injections were required.
Journal ArticleDOI
Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Ryan M. Rich,Philip J. Rosenfeld,Carmen A. Puliafito,Sander R. Dubovy,Janet L. Davis,Harry W. Flynn,Serafin Gonzalez,William J. Feuer,Richard C. Lin,Geeta A. Lalwani,Jackie K. Nguyen,Gaurav Kumar +11 more
TL;DR: Off-label intravitreal bevacizumab therapy for neovascular ARMD was well tolerated over 3 months with improvements in visual acuity and OCT central retinal thickness measurements.
Journal ArticleDOI
Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium
Chi-Chao Chan,James L. Rubenstein,Sarah E. Coupland,Janet L. Davis,J. William Harbour,Patrick B. Johnston,Nathalie Cassoux,Nathalie Cassoux,Valérie Touitou,Justine R. Smith,Tracy T. Batchelor,Jose S. Pulido +11 more
TL;DR: Because of the disease rarity, international, multicenter, collaborative efforts are required to better understand the biology and pathogenesis of PVRL as well as to define both diagnostic markers and optimal therapies.